Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Gerry Everlof"'
Autor:
Yan Shi, Ying Wang, Wei Meng, Robert P. Brigance, Denis E. Ryono, Scott Bolton, Hao Zhang, Sean Chen, Rebecca Smirk, Shiwei Tao, Joseph A. Tino, Kristin N. Williams, Richard Sulsky, Laura Nielsen, Bruce Ellsworth, Michael K. Y. Wong, Jung-Hui Sun, Leslie W. Leith, Dawn Sun, Dauh-Rurng Wu, Anuradha Gupta, Richard Rampulla, Arvind Mathur, Bang-Chi Chen, Aiying Wang, Helen G. Fuentes-Catanio, Lori Kunselman, Michael Cap, Jacob Zalaznick, Xiaohui Ma, Heng Liu, Joseph R. Taylor, Rachel Zebo, Beverly Jones, Stephen Kalinowski, Joann Swartz, Ada Staal, Kevin O’Malley, Lisa Kopcho, Jodi K. Muckelbauer, Stanley R. Krystek, Steven A. Spronk, Jovita Marcinkeviciene, Gerry Everlof, Xue-Qing Chen, Carrie Xu, Yi-Xin Li, Robert A. Langish, Yanou Yang, Qi Wang, Kamelia Behnia, Aberra Fura, Evan B. Janovitz, Nicola Pannacciulli, Steven Griffen, Bradley A. Zinker, John Krupinski, Mark Kirby, Jean Whaley, Robert Zahler, Joel C. Barrish, Jeffrey A. Robl, Peter T. W. Cheng
Publikováno v:
Journal of Medicinal Chemistry. 65:4291-4317
Autor:
Brian J. Murphy, Daniel Smith, Julia Sapuppo, Giridhar S. Tirucherai, Lawrence J. Kennedy, Ching-Hsuen Chu, Anthony V. Azzara, Shiwei Tao, Glenn D. Rosen, Subramaniam Krishnananthan, Jun Li, Victor R. Guarino, Lisa Burns, Joseph R. Taylor, Milinda Ziegler, Lakshmi Sivaraman, Bruce A. Ellsworth, Selvakumar Kumaravel, Hao Zhang, Tao Wang, Jun Shi, Atsu Apedo, Dhanusu Suresh, Kathy Mosure, Gerry Everlof, David A. Gordon, Lisa Zhang, Michael Gill, Chen-Pin Hung, Jianqing Li, Peter T. W. Cheng, Robert F. Kaltenbach, Sutjano Jusuf, Ying Wang, Stephanie Boehm, Mary Ellen Cvijic, Matthew G. Soars, Chi Shing Sum, Yan Shi, Jeffrey A. Robl, Reddigunta Ramesh Babu, Bradley A. Zinker, Yanou Yang, Stephen S. Kalinowski, Carrie Xu, Steven J. Walker, Sarah C. Traeger, Rebekah Heiry, Kimberley A. Lentz, Qian Ruan
Publikováno v:
Journal of Medicinal Chemistry. 64:15549-15581
The oxycyclohexyl acid BMS-986278 (33) is a potent lysophosphatidic acid receptor 1 (LPA1) antagonist, with a human LPA1 Kb of 6.9 nM. The structure-activity relationship (SAR) studies starting from the LPA1 antagonist clinical compound BMS-986020 (1
Autor:
Ching Kim Tye, Chunhong Yan, Sarah C. Traeger, Wayne Vaccaro, Yingru Zhang, Gerry Everlof, Jianqing Li, Henry Yip, Peng Li, John T. Hunt, Michael A. Poss, Gregory D. Vite, Mussari Christopher P, Steven Sheriff, Asoka Ranasinghe, Haiying Zhang, Richard A. Westhouse, Dharmpal S. Dodd, Richard Rampulla, Zheng Yang, Frank Marsilio, Derek J. Norris, Wen-Ching Han, Tram N. Huynh, Yufen Zhao, Patrice Gill, Nirmala Raghavan, Lalgudi S. Harikrishnan, Ashvinikumar V. Gavai, Susan Wee, John S. Tokarski, Dauh-Rurng Wu, Arvind Mathur, Mei-Li Wen, Huiping Zhang, David R. Tortolani, George V. Delucca, Krista Menard, Francis Y. Lee, Claude A. Quesnelle, Dawn Sun, Vijay T. Ahuja, Daniel O'malley, Christine Huang, Muthoni G. Kamau
Publikováno v:
Journal of Medicinal Chemistry. 64:14247-14265
Inhibition of the bromodomain and extra-terminal (BET) family of adaptor proteins is an attractive strategy for targeting transcriptional regulation of key oncogenes, such as c-MYC. Starting with the screening hit 1, a combination of structure-activi
Autor:
Vidya Perera, Jennifer Raftis, Samira Garonzik, Ronald Aronson, Joseph Luettgen, David E. Newby, Simon Wilson, Mohammed N. Meah, J. Gerry Everlof, Bindu Murthy
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology
Supplemental Digital Content is available in the text.
Objective: PAR (protease-activated receptor)-4 antagonism has antiplatelet effects under conditions of high shear stress. We aimed to establish whether PAR4 antagonism had additive antithrom
Objective: PAR (protease-activated receptor)-4 antagonism has antiplatelet effects under conditions of high shear stress. We aimed to establish whether PAR4 antagonism had additive antithrom
Autor:
Peter T W, Cheng, Robert F, Kaltenbach, Hao, Zhang, Jun, Shi, Shiwei, Tao, Jun, Li, Lawrence J, Kennedy, Steven J, Walker, Yan, Shi, Ying, Wang, Suresh, Dhanusu, Ramesh, Reddigunta, Selvakumar, Kumaravel, Sutjano, Jusuf, Daniel, Smith, Subramaniam, Krishnananthan, Jianqing, Li, Tao, Wang, Rebekah, Heiry, Chi Shing, Sum, Stephen S, Kalinowski, Chen-Pin, Hung, Ching-Hsuen, Chu, Anthony V, Azzara, Milinda, Ziegler, Lisa, Burns, Bradley A, Zinker, Stephanie, Boehm, Joseph, Taylor, Julia, Sapuppo, Kathy, Mosure, Gerry, Everlof, Victor, Guarino, Lisa, Zhang, Yanou, Yang, Qian, Ruan, Carrie, Xu, Atsu, Apedo, Sarah C, Traeger, Mary Ellen, Cvijic, Kimberley A, Lentz, Giridhar, Tirucherai, Lakshmi, Sivaraman, Jeffrey, Robl, Bruce A, Ellsworth, Glenn, Rosen, David A, Gordon, Matthew G, Soars, Michael, Gill, Brian J, Murphy
Publikováno v:
Journal of medicinal chemistry. 64(21)
The oxycyclohexyl acid BMS-986278 (
Autor:
Andrew P. Degnan, Haiquan Fang, Tatyana Zvyaga, Zuzana Haarhoff, Claude A. Quesnelle, Melissa Kramer, Frank Marsilio, Richard A. Westhouse, John S. Tokarski, Shilpa Madari, Jiuqiao Zhao, Amy Wiebesiek, Chunhong Yan, Francis Y. Lee, Michael Sinz, John Morrison, Jean Simmermacher-Mayer, Carolynn Fanslau, Steven Sheriff, Lisa Huang, Ashvinikumar V. Gavai, Chunshan Xie, Matthew D. Hill, Gerry Everlof
Publikováno v:
Bioorganicmedicinal chemistry letters. 51
We describe our efforts to introduce structural diversity to a previously described triazole-containing N1-carboline series of bromodomain and extra-terminal (BET) inhibitors. N9 carbolines were designed to retain favorable binding interactions that
Autor:
Chunhong Yan, Francis Y. Lee, Ashvinikumar V. Gavai, Melissa Kramer, Frank Marsilio, Eric Shields, Laura Monereau, Zuzana Haarhoff, Richard A. Westhouse, Lisa Zhang, Gerry Everlof, John S. Tokarski, Matthew D. Hill, Tatyana Zvyaga, Asoka Ranasinghe, Carolynn Fanslau, Ching Kim Tye, Steven Sheriff, Christine Huang, Andrew P. Degnan, Krista Menard, John Morrison, Haiquan Fang
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 44:128108
We describe our efforts to identify structurally diverse leads in the triazole-containing N1-carboline series of bromodomain and extra-terminal inhibitors. Replacement of the N5 “cap” phenyl moiety with various heteroaryls, coupled with additiona
Autor:
Ivar M. McDonald, Wang Nenghui, Victor R. Guarino, Kimberley A. Lentz, Richard E. Olson, Wendy Clarke, Roy Haskell, J. Gerry Everlof
Publikováno v:
Bioorganicmedicinal chemistry letters. 30(3)
The objective of this Letter is to report the first (to our knowledge) in vivo proof of concept for a sulfenamide prodrug to orally deliver a poorly soluble drug containing a weakly-acidic NH–acid from a conventional solid dosage formulation. This
Autor:
Hong Wu, Gary L. Schieven, Joel C. Barrish, Bei Wang, Bang Chi Chen, Sam T. Chao, Gerry Everlof, Jung Hui Sun, Chunjian Liu, John H. Dodd, Murray McKinnon, Kathleen M. Gillooly, Katerina Leftheris, John Hynes, Tracy L. Taylor, Vivekananda M. Vrudhula, T. G. Murali Dhar, Stephen T. Wrobleski, Hongjian Zhang, David J. Shuster, Shuqun Lin, Kim W. McIntyre, Rulin Zhao, Christoph Gesenberg, James Lin, Punit Marathe
Publikováno v:
Journal of Medicinal Chemistry. 58:7775-7784
In search for prodrugs to address the issue of pH-dependent solubility and exposure associated with 1 (BMS-582949), a previously disclosed phase II clinical p38α MAP kinase inhibitor, a structurally novel clinical prodrug, 2 (BMS-751324), featuring
Autor:
Claude A. Quesnelle, Patrice Gill, Richard Rampulla, Ching Su, Gerry Everlof, George L. Trainor, Ke Chen, Vinod Arora, Richard A. Westhouse, Celia D’Arienzo, Andrew J. Tebben, Weifang Shan, John T. Hunt, Derek J. Norris, Louis J. Lombardo, Zheng Yang, Arvind Mathur, Mei-Li Wen, Yingru Zhang, Dauh-Rurng Wu, Wen-Ching Han, Krista Menard, Victor R. Guarino, Asoka Ranasinghe, Richard E. Olson, Ashvinikumar V. Gavai, Bruce S. Fischer, Phil S. Baran, Anne Rose, Lan Xiao, Ronald E. White, Mary Ellen Cvijic, Gregory D. Vite, Ding Ren Shen, Jere E. Meredith, Haiqing Wang, Francis Y. Lee, Aaron Balog
Publikováno v:
ACS Medicinal Chemistry Letters. 6:523-527
Structure-activity relationships in a series of (2-oxo-1,4-benzodiazepin-3-yl)-succinamides identified highly potent inhibitors of γ-secretase mediated signaling of Notch1/2/3/4 receptors. On the basis of its robust in vivo efficacy at tolerated dos